PIPELINE

New Cases of

Pancreatic Cancer

diagnosed in 2017

Estimated Deaths of

Pancreatic Cancer

in 2017

5-Year Survival 

 
 
 
 
 

ABOUT US

TEAM

CONTACT

 ​Pancreatic Cancer is one of the most aggressive cancers
with a 5-year survival of 8%. NomoCan’s NMC-001 is a selective and specific monoclonal antibody that is the first in its kind to be developed for pancreatic cancer. NomoCan’s NMC-001 effectively targets cancer cells without harming normal cells and therefore will not have the side effects of non-specific chemotherapeutic agents currently in the clinic. 
NomoCan Pharmaceuticals offers first-in-kind targeted therapies for some of the most aggressive cancers with unmet medical need. Our platform technology not only makes available a selective and specific diagnostic and prognostic test for early detection, but more remarkably, 
it introduces a highly effective monoclonal antibody (mAb) drugs for the treatment of various cancers in order to 
“Bring Hope” to patients affected by this devastating disease.​

Ehsan Sarafraz-Yazdi, Ph.D., M.P.H.

Co-Founder & Chief Executive Officer

Bring Hope

Josef Michl, M.D.

Scientific Advisor

Kamyar Neshvadian, M.S., F.R.M.

Chief Financial Officer

Victor Adler, M.D., Ph.D.

Senior Scientist

Brad Evans, Ph.D.

Senior Scientist

Dallas Broadway, M.D.

Clinical Advisor

Emil Lou, M.D., Ph.D.

Scientific Advisor

Lisa Wisniewski, Ph.D.

Regulatory Advisor

NomoCan Pharmaceuticals LLC

310 E 67th Street, Suite 1-45

New York, NY 10065

Our Address
For more information, please contact us below.

© 2017 NomoCan All Rights Reserved.

Benjamin Mumford, M.S. 

Research Associate